Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Nations stockpile mpox vaccine amid rising geopolitical fears
9 Jul 2025, 14:48BAVA.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Bavarian Nordic A/S - Articles of Association30 Apr 2018
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held April 17, 201817 Apr 2018
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting26 Mar 2018
Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus16 Mar 2018
Bavarian Nordic Awards Restricted Stock Units to Executive Management12 Mar 2018
Bavarian Nordic Announces Annual Report 201712 Mar 2018
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer8 Mar 2018
Search

Danish vaccine maker Bavarian Nordic will supply an undisclosed European country with its smallpox and mpox vaccine under a new contract valued at over 200 million Danish Krone, the company announced Wednesday.

Bavarian Nordic sells vaccine voucher for $160 million
20 Jun 2025, 17:26BAVA.CONASDAQ Copenhagen

Danish vaccine company Bavarian Nordic has entered an agreement to sell a Priority Review Voucher for a total of $160 million, the company said Wednesday.

  • Previous
  • 1
  • 2
  • 3
  • Next
Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine6 Mar 2018
Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers26 Feb 2018
Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine6 Feb 2018
Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen31 Jan 2018
Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis19 Jan 2018
  • Previous
  • 1
  • More pages
  • 28
  • 29
  • 30
  • More pages
  • 78
  • Next
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
Filings
927